Managing bone mineral disorders in CKD: an overview of current therapies.
Delaney
Michael
M
Department of Renal Medicine, East Kent Hospitals, NHS University Trust, Canterbury, Kent, UK. michael.delaney@ekht.nhs.uk
D000465:Algorithms; D015415:Biomarkers / Q000097:blood; D002117:Calcitriol / Q000191:economics / Q000627:therapeutic use; D002118:Calcium / Q000097:blood; D002614:Chelating Agents / Q000191:economics / Q000627:therapeutic use; D012080:Chronic Kidney Disease-Mineral and Bone Disorder / Q000175:diagnosis / Q000209:etiology / Q000378:metabolism / Q000628:therapy*; D003663:Decision Trees; D006801:Humans; D054559:Hyperphosphatemia / Q000175:diagnosis / Q000209:etiology / Q000378:metabolism / Q000628:therapy*; D007676:Kidney Failure, Chronic / Q000150:complications*; D009398:Nephrology / Q000379:methods* / Q000592:standards; D010281:Parathyroid Hormone / Q000097:blood; D016105:Parathyroidectomy; D010348:Patient Care Team; D010353:Patient Education as Topic; D010758:Phosphorus / Q000097:blood; D017410:Practice Guidelines as Topic; D012680:Sensitivity and Specificity; D016896:Treatment Outcome; D014807:Vitamin D / Q000031:analogs & derivatives
D015415:Biomarkers; D002614:Chelating Agents; D010281:Parathyroid Hormone; D014807:Vitamin D; D010758:Phosphorus; D002117:Calcitriol; D002118:Calcium